bioProcessUK: The role of candidate screening and feasibility studies

Ian Goodwin.png

Ahead of the 20th annual bioProcessUK conference next week in Brighton, Ian Goodwin, Director of CMC Program Design in Advanced Therapies (covering Cell and Gene Therapy services) at FUJIFILM Diosynth Biotechnologies explores the benefits of candidate and feasibility studies to AAV production.


Drug developers in the adeno-associated virus (AAV) therapy space are up against several challenges and limitations as they work to deliver innovative therapeutics to patients. Perhaps most notably, limited funding that has become increasingly gated, that is, requiring programs to reach certain milestones before additional resources are unlocked. CDMOs should understand the challenges that investigators face when it comes to raising funding, and in turn, offer solutions.

Candidate screening and feasibility studies are efficient and effective mechanisms that can provide material enabling generation of clinical data to support the next round of funding. Specifically, candidate screening should narrow down the most promising AAV constructs from a manufacturing and clinical efficacy standpoint and evaluate critical quality attributes.

Candidate screening requires a minimal amount of bioprocessing, generally a shake flask or small stirred tank bioreactor’s worth. It allows screening of multiple different candidates simultaneously which are run through a common downstream process. Previously, less readily scalable methods like ultracentrifugation or precipitation followed by ultracentrifugation were commonly used. At FDB, we moved away from these to identify a more manufacturing-ready process to rapidly evaluate as many different constructs as possible.

Gain more insight with feasibility studies 

Once construct design is complete and the most promising AAV constructs identified, subsequent feasibility studies include scale-up, additional material for your preclinical studies, biodistribution analysis, and dose range finding prior to toxicology design. They provide a more expansive product quality and residual panel of analytics, including genome titer, full-to-empty ratio analysis, capsid titers, residual host cell DNA, and host cell protein. These are critical to ensure process performance and scalability.  As such, feasibility studies enable success criteria to be established prior to moving into process development and demonstration runs and secure additional material for preclinical studies.

Choose a modular approach to suit your needs 

While there are a variety of entry points to a CDMO partnership, it is critical to design a path that accommodates the needs of your project. At FDB, we offer our clients several modular paths, that allow the project’s scope to shift with a client’s needs. Our full program encompasses candidate screening, feasibility studies, small-scale process/analytical development, toxicology material generation, cGMP, and release.  

If you are curious about how candidate screening and feasibility studies could help you, view the recent webinar hosted by FDB on the impact of candidate and feasibility studies for AAV therapeutics. 

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Manufacturing Organisation with locations in Billingham, UK and Research Triangle Park, North Carolina, USA.

FUJIFILM Diosynth Biotechnologies has over 25 years’ combined experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial, mammalian, and insect systems. The company offers a comprehensive list of services from cell line development, including its proprietary pAVEway™ system, to process development, analytical development, clinical and commercial manufacturing. Both sites are FDA-approved for the production of commercial products.

 

Meet and learn more about FUJIFILM Diosynth Biotechnologies at the 20th Annual bioProcessUK conference


More news and updates 

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Demand for Golden Triangle lab space surges with highest annual volume since 2015

Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

New £100 million engineering biology fund

Six new Engineering Biology Mission Hubs and 22 Mission Awards, to transform solutions in areas like vaccine development, textile manufacturing and food production; New investments to unlock potential of engineering biology as part of the wider National Engineering Biology Programme

Pioneer Group’s regeneration plans for Cambridge’s Grafton Centre approved

Pioneer Group, a leading developer and operator of life science and high-tech campuses, has secured planning permission from Cambridge City Council, subject to S106, for the redevelopment of the Grafton Centre in the city.

Novel drug and software combo tackles hypertension with personalised treatment

Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalised dose optimisation, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1).

 

More within